Spago Nanomedical Gets Regulatory Approval To Begin Phase Iia Study Trial With Mri Contrast Agent Sn132D In Endometriosis

Spago Nanomedical Ab (Publ), Swedish Nanomedicines Company, Announced That The Company Has Received Regulatory Approval To Initiate A Phase Iia Clinical Study With Its Mri Contrast Agent Sn132D In Endometriosis